Atlas Trials

A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes

Clinical trial NCT01589159 · COMPLETED

Trial details

NCT number
NCT01589159
Sponsor
Tao OUYANG
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2013-01-01
Primary completion
2016-07-01
Enrollment
54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.